Equaly Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

Equaly General Information

Description

Developer of a platform technology designed to activate peptide-specific natural killer T cells for the treatment of tumors and intracellular infections. The company offers a CD1d (Cluster of Differentiation 1d)-based approach that targets hydrophobic peptides and uses naturally occurring effector memory T cells, enabling researchers and pharmaceutical companies to develop treatments for cancer and infectious diseases using activated NKT cells (Natural Killer T cells) and antibody-drug conjugates carrying CD1d-restricted epitopes.

Contact Information

Website
www.equaly.be
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Chemin du Cyclotron 6
  • 1348 Louvain-la-Neuve
  • Belgium
+32 02
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Vertical(s)
HealthTech
Corporate Office
  • Chemin du Cyclotron 6
  • 1348 Louvain-la-Neuve
  • Belgium
+32 02

Equaly Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Equaly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 12-Aug-2026 Completed Pre-Clinical Trials
2. Accelerator/Incubator 11-Feb-2026 Completed Product In Beta Test
1. Later Stage VC 27-Aug-2021 $2.83M $2.83M Completed Product In Beta Test
To view Equaly’s complete valuation and funding history, request access »

Equaly Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class B
Class B
To view Equaly’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Equaly Patents

  • 38

    Total Documents Applications and Grants

  • Total Patents Families

  • 24

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Equaly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021306572-A1 Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen Active 06-Jul-2020
AU-2021306572-B2 Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen Active 06-Jul-2020
CA-3183598-A1 Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen Pending 06-Jul-2020
EP-4176264-A1 Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen Active 06-Jul-2020
EP-4176264-B1 Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen Active 06-Jul-2020 C07K14/70539
To view Equaly’s complete patent history, request access »

Equaly Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Equaly Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Peachscore Accelerator/Incubator
Viralety Ventures Venture Capital Minority
To view Equaly’s complete investors history, request access »

Ready to get started?

Request a free trial

Equaly FAQs

  • When was Equaly founded?

    Equaly was founded in 2016.

  • Where is Equaly headquartered?

    Equaly is headquartered in Louvain-la-Neuve, Belgium.

  • What is the size of Equaly?

    Equaly has 3 total employees.

  • What industry is Equaly in?

    Equaly’s primary industry is Other Healthcare Technology Systems.

  • Is Equaly a private or public company?

    Equaly is a Private company.

  • What is Equaly’s current revenue?

    The current revenue for Equaly is .

  • How much funding has Equaly raised over time?

    Equaly has raised $2.83M.

  • Who are Equaly’s investors?

    Peachscore and Viralety Ventures have invested in Equaly.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process